EMBC · Embecta Corp.

Embecta Corp. has completed its strategic acquisition of Owen Mumford Holdings Limited, a UK-based innovator in medical devices and drug-delivery technologies, marking a key milestone in its transformation into a broad-based medical supplies company. The transaction, initially announced via a definitive Purchase Agreement dated March 19, 2026, involved sellers including Mark Owen, Adam Mumford, Anne Mumford, Ellen Owen, Kim Priddis, and Nancy Millington. Financial terms include an upfront cash payment of £100 million at closing, adjustable for customary items like net cash, with potential additional payments up to £50 million tied to commercial milestones on sales of the Aidaptus® next-generation auto-injector platform through June 30, 2029. This deal integrates Owen Mumford's expertise in device design, molding, assembly, and intellectual property with Embecta's global commercial infrastructure and manufacturing scale, targeting expansion in chronic care markets such as obesity, diabetes, autoimmune diseases, and anaphylaxis. The acquisition enhances Embecta's drug-delivery offerings for pharmaceutical partners and broadens its product portfolio in self-injection and diagnostics, potentially driving geographic reach and operational synergies. A press release dated May 15, 2026, was issued under Regulation FD, with the full Purchase Agreement available as Exhibit 2.1 from the prior 8-K filing.